Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of SHAPE
administered topically to skin lesions in patients with early-stage cutaneous T-cell lymphoma
(CTCL).